SCHEMBL13484342

SCHEMBL13484342

CCc1cccc(-c2ccc(C=O)s2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2E1 P05181 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2A6 P11509 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2B6 P20813 1/20 0.50
CYP2C19 P33261 1/20 0.50
APP P05067 1/20 0.49
PRF1 P14222 1/20 0.45
MAPT P10636 2/20 0.43
BCL2 P10415 1/20 0.42
ALDH1A1 P00352 1/20 0.41
DPP4 P27487 1/20 0.41
PGR P06401 1/20 0.41
NOTUM Q6P988 1/20 0.38
PTGS2 P35354 1/20 0.38
TP53 P04637 1/20 0.38
IDO1 P14902 1/20 0.38
KDM4E B2RXH2 1/20 0.38
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27318188 0.84 CYP2E1 (0.50) CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6
SCHEMBL14026672 0.80 HSD17B2 (0.53) CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6
SCHEMBL7010956 0.79 CYP2A6 (0.54) CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6
SCHEMBL2217719 0.78 HSD17B2 (0.52) APPHSD17B1HSD17B2
SCHEMBL70783 0.77 APP (0.67) CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6
SCHEMBL12622765 0.77 IDO1 (0.45) CYP3A4CYP2C19BCL2PGRNOTUM
SCHEMBL2019002 0.76 PRF1 (0.56) CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6
SCHEMBL9199395 0.76 CYP2E1 (0.54) CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6
SCHEMBL2016059 0.76 HSD17B1 (0.56) CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6
SCHEMBL5760473 0.76 CYP2E1 (0.54) CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7667036-B2 MAPKAP-K2 (mitogen-activated protein kinase-activated protein kinase 2) inhibitors; inflammatory, autoimmune disease, destructive bone disorder, cancer and/or tumor growth; angiogenesis, diabetes and neurological disorders TEIJIN PHARMA LIMITED (JP) 2010-02-23 US disclosed